Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS. Data from a systematic review and meta-analysis of 20 studies demonstrated that luspatercept-aamt (Reblozyl) yielded high red blood…
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts…
Simple Summary Acute myeloid leukemia is a life-threatening blood cancer with many treatment options, but outcomes vary depending on a person’s age and the genetic changes in their cancer cells. While some new therapies have improved remission rates and survival, certain subtypes…
Abstract QuANTUM-First was a randomized trial that demonstrated that the addition of quizartinib, a potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, to induction and consolidation chemotherapy, followed by monotherapy maintenance, improved the survival for…
Recent advances in whole-genome and next-generation sequencing (NGS) have significantly deepened our understanding of the genomic landscape of acute myeloid leukemia (AML), uncovering not only somatic mutations but also inherited germline predispositions.1,2 While somatic NGS…
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2…
ABSTRACT The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease…
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2…
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for aplastic anemia (AA), especially in younger patients with matched sibling donors (MSD). However, in low-resource settings, delayed access to HSCT and pre-transplant complications can…
Abstract The intensity of the conditioning regimen in hematopoietic stem cell transplantation (HSCT) correlates with the risk of relapse, however its potential benefit may be outweighed by the associated risk of toxicity. The addition of total marrow irradiation (TMI) to…